Revvity vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Revvity Inc. (RVTY)

Q3 202617 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

August 202617 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

Latest17 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.